Clinical trials: Mucosal Infection
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Viral Infections
A Study of Intranasal LMN-1001 in Healthy Adults
The purpose of this study is to optimize the tolerability of LMN-1001 relative to its ability to activate the host immune response. LMN-1001 is an investigational dry powder containing recombinant interferon lambda (IFN-λ).
- Trial name
- NCT07852208
- Testing
- LMN-1001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Gonorrhoea
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae…
- Trial name
- NCT04722003
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Influenza
The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine
This is a single-center, randomized, open-label trial designed to explore the interaction between mucosal microbiota colonization in the nasal cavity and gut and the immune response to an intranasal live attenuated influenza…
- Trial name
- NCT06609811
- Testing
- Intranasal Influenza Live Attenuated Vaccine
- Where
- China
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Shigella
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
- Trial name
- NCT01531530
- Testing
- CVD 1208S, a Shigella flexneri 2a live, oral vaccine
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Poliomyelitis
Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
This is a single site, phase 1 study of dmLT as a mucosal adjuvant to control fecal viral shedding when used in combination with intradermally administered fractional dose trivalent IPV (fIPV).
- Trial name
- NCT05327426
- Testing
- Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
IPF, Sarcoidosis
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and COPD. Similar sampling from healthy controls for comparative data.
- Conditions
- IPF, Sarcoidosis, Tuberculosis, Asthma
- Trial name
- RESPI-SAM (NCT02807025)
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Poliomyelitis
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and…
- Trial name
- NCT07010822
- Testing
- nOPV2
- Where
- Bangladesh
- Volunteers
- 740 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Covid19
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents…
- Trial name
- NCT04842305
- Testing
- Blood- and saliva tests
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lenanrt Friis-Hansen
Human Immunodeficiency Virus (HIV)
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.
- Trial name
- NCT01053741
- Testing
- Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Vaccinia, Virus Diseases
Evaluating the Human Immune Response to the JYNNEOS Vaccine
This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
- Trial name
- NCT06366672
- Testing
- JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HIV Infections
Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women
Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease-causing agents.
- Trial name
- NCT00594373
- Testing
- Tenofovir gel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
The purpose of this study is to determine the safety and immune system response to the TBC-3B HIV vaccine when it is injected either into the groin area or into the arm.
- Trial name
- NCT00056745
- Testing
- TBC-3B
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally
Influenza is a virus infection that causes sickness from the nose to the lungs. It is thought that type 1 interferon (a protein that helps the immune system fight viruses) will make flu vaccines more effective.
- Trial name
- NCT00436046
- Testing
- Trivalent inactivated influenza virus vaccine (2006-2007 formulation), Type 1 interferon
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Acquired Immune Deficiency Syndrome
Reactogenicity and Immunogenicity of Vaginal CNgp140
To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.
- Trial name
- SG06RS02 (NCT00637962)
- Testing
- HIV glycoprotein CN54gp140 (vaccine), Carbopol 974
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
COVID - 19
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection.
- Trial name
- NCT06768697
- Testing
- KFD1(0µg ), KFD1(20µg), KFD1(40µg)
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Public Health Clinical Center
Mumps, Measles
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination.
- Conditions
- Mumps, Measles, Rubella
- Trial name
- MIPS (NCT05894395)
- Testing
- MMR booster vaccination (as M-M-R-VaxPro)
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Zurich